|
|
The Clinical Efficacy and Safety of Stem Cell Therapy for Diabetes Mellitus: A Systematic Review and Meta-Analysis
|
Yazhen Zhang, Wenyi Chen, Bing Feng, Hongcui Cao
|
|
|
Table 1 Characteristics of the included studies. |
|
Author and year | Country | Sample size (cell therapy/ control) | Male (%) (cell therapy/control) | Mean age (cell therapy/control) (years) | History of DM | Regimen | Regimens (cell number) dose | Injection mode | Mean follow-up period |
---|
Ye 2017 [25] | China | 8/10(T1DM) | 37.5% /40% | 18.86 /20.18 | <6 m | BM-HSC | NA | IV | 12 m | D'Addio 2014 [18] | Poland | 65(T1DM) | 63% | 20.4 | <12 m | BM-HSC | 5.8 ×l06 /kg | IV | 48 m | Zhang 2012 [26] | China | 9(T1DM) | 55.6% | 17.6 | 2 y | BM-HSC | 12.31 ×l06 /kg | IV | 12 m | Li 2012 [39] | China | 13(T1DM) | 69.2% | 14.1 | <12 m | BM-HSC | 4 ×l06 /kg | IV | 42 m | Gu 2012 [44] | China | 28(T1DM) | 50% | 17.6 | 3 m | BM-HSC | NA | IV | 19.3 m | Snarski 2010 [24] | Poland | 8(T1DM) | 50% | 25.8 | 2 m | BM-HSC | 4.14×l06 /kg | IV | 7 m | Couri 2009 [28] | Brazil | 23(T1DM) | 73.9% | 18.4 | <2 m | BM-HSC | 10.52×l06 /kg | IV | 29.8 m | Voltarelli 2007 [16] | Brazil | 15(T1DM) | 73.3% | 19.2 | <2 m | BM-HSC | 11 ×l06 /kg | IV | 18.8 m | Carlsson 2014 [27] | Sweden | 9/9(T1DM) | 88.9% /55.6% | 24 /27 | <3 w | MSC | 2.75 ×l06 /kg | IV | 12 m | Hu 2013 [36] | China | 15/14(T1DM) | 60% /57.1% | 17.6 /18.2 | New onset | MSC | 2.6 ×107/kg | IV | 21 m | Bhansali 2017 [23] | India | 10/10(T2DM) | 80% /60% | 50.5 /53.5 | 14.5 y | MSC | 1 ×l06 /kg | Superior pancreatico-duodenal artery | 12 m | Hu 2016 [34] | China | 31/30(T2DM) | 54.8% /53.3% | 52.43 /53.21 | 8.95 /8.3 y | MSC | 6.1 ×107 | IV | 36 m | Skyler 2015 [47] | USA | 45/16(T2DM) | 62.2% /75% | 56.7 /58.7 | 10.1y | MSC | 1.1×106/kg | IV | 12 w | Guan 2015 [48] | China | 6(T2DM) | 100% | 40.5 | 42.7 w | MSC | 0.88×106/kg | IV | 33.2 m | Liu 2014 [30] | China | 22(T2DM) | 68.18% | 52.9 | 8.7 y | MSC | 1×106/kg | IV on Day 5+ Splenic artery on Day 10 | 12 m | Jiang 2011 [29] | China | 10(T2DM) | 70% | 66 | 11 y | MSC | 1.35 ×106 | IV | 6 m | Bhansali 2017 [33] | India | 7(T2DM) | 85.7% | 46 | 15 y | BM-MNC | 1.2 ×109 | Superior pancreatico-duodenal artery | 6 m | Bhansali 2017 [23] | India | 10/10(T2DM) | 70% /60% | 44.5 /53.5 | 13.5 y | BM-MNC | 1 ×109 | Superior pancreatico-duodenal artery | 12 m | Wu 2014 [32] | China | 20/20(T2DM) | 60% /55.5% | 56.4 /54.9 | 9.7 y | BM-MNC | 4.01×109 | Dorsal pancreatic artery | 12 m | Bhansali 2014 [31] | India | 11/10(T2DM) | 81.8% /70% | 51 /54 | 15.8 y | BM-MNC | 2.9 ×108 | Superior pancreatico-duodenal artery | 12 m | Hu 2012 [35] | China | 56/62(T2DM) | 67.8% /58% | 50.4 /50.2 | 8.6 y | BM-MNC | 2.8 ×109 | Dorsal pancreatic artery | 33 m | Bhansali 2009 [17] | India | 10(T2DM) | 80% | 57.5 | 14.6 y | BM-MNC | 3.5 × 108 | Superior pancreatico-duodenal artery | 6 m |
|
|
|